Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

For patients with multiple myeloma, the use of novel agents in first-line triplet and quadruplet induction regimens -- with or without high-dose therapy and autologous stem cell transplant (ASCT) -- ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Number one is, given the high degree of efficacy that the CAR T cells have, there's a great interest in knowing should we really be waiting for giving these CAR T cells to patients with relapse and ...

During a live event, Jeffrey V. Matous, MD, discussed flexible dosing and the need to expand use in community practices for ...

In this exclusive MedPage Today video, investigator Shahzad Raza, MD, of the Cleveland Clinic Cancer Institute, explains why ...

Signs and Symptoms That Occur With Multiple Myeloma As cancerous plasma cells multiply within the bone marrow, they reveal their presence in a number of ways. The main three tend to be: Bone Pain ...

U.S. and China Tariffs, New Treatment for Multiple Myeloma, SRP Light Up Project For Navajo Nation The United States and China announced a 90-day pause on most of their recent tariffs on each ...

Conoley, A. J., et al. (2025). Therapy-related B-lymphoblastic Leukemia Following Treatment for Multiple Myeloma with Unusual Surface Light Chain Expression: A Case Report. Journal of Clinical and ...

"Studies show that [multiple] myeloma is associated with more than 400 canonical somatic mutations per patient, and the most commonly mutated genes include immunoglobulin heavy chain and light ...

Monoclonal free light chains (FLCs) frequently cause rapidly progressive renal failure in patients with multiple myeloma. Immunoassays which provide quantitative measurement of FLCs in serum, have ...